ISIN:DE000A32VN83

EQS-News: Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023

Retrieved on: 
Dienstag, Oktober 17, 2023
News, USD, EBITDA, Supervisory board, AG, Epigenomics AG, RTÉ Executive Board, Patient, Sale, Epigenomics, Security (finance), Bank, Rare-earth element

As a result, almost all of the Company's assets have been transferred to New Day Diagnostics.

Key Points: 
  • As a result, almost all of the Company's assets have been transferred to New Day Diagnostics.
  • As part of the closing, the Company has received as consideration a cash payment of USD 0.5 million and an interest in New Day Diagnostics.
  • Jens Ravens, Executive of Epigenomics AG: “The transfer of almost all assets now completed represents the closing of the sale which was overwhelmingly approved by our Extraordinary General Meeting on September 11, 2023.
  • The adjustment results essentially from the income for the year 2023 from the contract with New Day Diagnostics.

EQS-News: Epigenomics AG: Pareto and Warburg publish analyst research reports

Retrieved on: 
Dienstag, September 5, 2023
Warburg, Epigenomics AG, Supervisory board, Research, Sale, EUR, RTÉ Executive Board, Hold, Southwestern Advantage, Pareto, Cryptocurrency, Epigenomics

Berlin (Germany), September 5, 2023 - Epigenomics AG (Frankfurt General Standard: ECX1; the "Company") announces that the research reports recently published by Pareto Securities AS and Warburg Research GmbH issue buy recommendations for Epigenomics AG's share.

Key Points: 
  • Berlin (Germany), September 5, 2023 - Epigenomics AG (Frankfurt General Standard: ECX1; the "Company") announces that the research reports recently published by Pareto Securities AS and Warburg Research GmbH issue buy recommendations for Epigenomics AG's share.
  • Both analysts consider the sale of substantial assets to New Day Diagnostics LLC as a chance to realize the potential and value of Epigenomics' blood-based colorectal cancer test Epi proColon “Next-Gen”.
  • With the shift from "Hold" to "Buy", Warburg even indicates that they consider the sale of significant assets likely to be more advantageous for shareholders than a further independent development.
  • Pareto and Warburg set the price target at EUR 3.15 and EUR 3.30, respectively, subject to approval by Epigenomics AG's shareholders at the Extraordinary General Shareholders' Meeting on September 11, 2023, in Berlin.

EQS-News: Epigenomics AG publishes financial results for the first six months 2023

Retrieved on: 
Donnerstag, August 10, 2023
Executive, CMS, Fairness, Epigenomics AG, Supervisory board, FSE, USD, Sale, Medicare, EUR, Federal Executive Boards, EBITDA, IDW, ECX, Supervision, R, FDA, German Institute for Economic Research, Raute (company), Security (finance), Pharmaceutical industry, Bank, Audit, Lithium, Epigenomics

Berlin (Germany), August 10, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2023.

Key Points: 
  • Berlin (Germany), August 10, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2023.
  • Ultimately, an agreement was reached with New Day Diagnostics LLC on July 24, 2023, to sell substantially all of Epigenomics' assets.
  • In terms of cash consumption, Epigenomics forecasts a range of EUR 7.0 million to EUR 9.0 million for the current full year 2023.
  • The interim statement for the first half of 2023 (unaudited) can be found on Epigenomics' website at: https://www.epigenomics.com/news-investors/financial-reports/ .

EQS-News: Epigenomics AG Announces Successful Agreement on the Acquisition of Significant Assets

Retrieved on: 
Montag, Juli 24, 2023
CMS, Extraordinary general meeting, Epigenomics AG, Mass meeting, Biomarker, USD, Sale, Death, Aktiengesellschaft, Patent, ECX, OTCQX, Epigenomics, Security (finance), Pharmaceutical industry

This agreement is the result of negotiations previously disclosed in the ad hoc announcement dated June 12, 2023.

Key Points: 
  • This agreement is the result of negotiations previously disclosed in the ad hoc announcement dated June 12, 2023.
  • The agreement will be made available on Epigenomics AG's website as of the convening of the Extraordinary General Meeting.
  • Jens Ravens, Executive of Epigenomics AG, emphasizes the importance of the agreement: "The further development and commercialization of the "Next-Gen"-Test requires significant resources that we as a company can no longer provide.
  • The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon "Next-Gen" and secure future cash flows for Epigenomics AG.

EQS-News: ​​​​​​​Epigenomics AG Reports Financial Results for the First Quarter of 2023

Retrieved on: 
Donnerstag, Juni 1, 2023
Executive, General Standard, Frankfurt Stock Exchange, Epigenomics AG, Supervisory board, FSE, Research, EUR, EBITDA, RTÉ Executive Board, ECX, EPI, FDA, Film industry, Pharmaceutical industry, Lithium, Epigenomics

Berlin (Germany) and San Diego, CA (USA), May 31, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2023.

Key Points: 
  • Berlin (Germany) and San Diego, CA (USA), May 31, 2023 - Epigenomics AG (FSE: ECX, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2023.
  • Revenues in the first quarter of 2023 increased slightly year-on-year from EUR 115 thousand to EUR 134 thousand.
  • Cash consumption decreased slightly to EUR 3,272 thousand in the first quarter of 2023 (Q1 2022: EUR 3,408 thousand).
  • On April 12, 2023, the Company announced the resignation of Chief Executive Officer Greg Hamilton effective June 30, 2023.